一名重症 COVID-19 肺炎患者的皮肤毛霉病：一份极其罕见的病例报告。
Cutaneous Mucormycosis in a Patient of Severe COVID-19 Pneumonia: A Rarer than Rare Case Report.
作者信息
Tambe Rahul R, Hinduja Anupa, Sunil Suchithra, Varaiya Ami, Joshi Amol
机构信息
Department of Internal Medicine, Nanavati Max Super Specialty Hospital, Mumbai, Maharashtra, India.
Department of Microbiology, Nanavati Max Super Specialty Hospital, Mumbai, Maharashtra, India.
出版信息
Indian J Crit Care Med. 2021 Nov;25(11):1318-1319. doi: 10.5005/jp-journals-10071-24026.
UNLABELLED
Coronavirus disease-2019 (COVID-19)-associated mucormycosis is on the rise in the Indian subcontinent. We report a unique case of cutaneous mucormycosis in a case of newly diagnosed young diabetic patient with severe COVID-19 pneumonia with post-COVID lung fibrosis. Neither did he have any preceding trauma or wound, nor was there any evidence of any secondary dissemination. Cutaneous mucormycosis without evidence of either is unheard off. Possible risk factors in this case were multiple bacterial secondary infections with the use of higher antibiotics, use of voriconazole for possible aspergillosis, and steroid use.
HOW TO CITE THIS ARTICLE
Tambe RR, Hinduja A, Sunil S, Varaiya A, Joshi A. Cutaneous Mucormycosis in a Patient of Severe COVID-19 Pneumonia: A Rarer than Rare Case Report. Indian J Crit Care Med 2021;25(11):1318-1319.
未标注
2019冠状病毒病（COVID-19）相关的毛霉病在印度次大陆呈上升趋势。我们报告了一例独特的皮肤毛霉病病例，患者为一名新诊断的年轻糖尿病患者，患有重症COVID-19肺炎并伴有COVID-19后肺纤维化。他既没有任何先前的创伤或伤口，也没有任何继发播散的证据。没有上述任何一种证据的皮肤毛霉病闻所未闻。该病例可能的危险因素包括因使用更高级别的抗生素导致的多种细菌继发感染、因可能的曲霉病使用伏立康唑以及使用类固醇。
如何引用本文
Tambe RR, Hinduja A, Sunil S, Varaiya A, Joshi A. 重症COVID-19肺炎患者的皮肤毛霉病：一例极为罕见的病例报告。《印度重症监护医学杂志》2021年；25(11):1318 - 1319。
Zotero 插件